
Insmed (INSM) Stock Forecast & Price Target
Insmed (INSM) Analyst Ratings
Bulls say
Insmed Inc. has identified a patient population of 500,000 to 1 million diagnosed patients for its products, with significant market growth potential due to misdiagnosis rates in related diseases. The company is projecting full-year 2025 global revenue for its commercial product ARIKAYCE in the range of $405 million to $425 million, while the anticipated launch of Brensocatib shows promise for reaching peak sales of approximately $8.2 billion due to high physician demand. Additionally, Insmed's expansion of its commercial infrastructure, including the addition of 120 sales representatives and plans for further market access improvements, combined with potential label expansions for its existing products, suggests a robust pipeline that could deliver substantial financial upside.
Bears say
Insmed Inc faces significant challenges that contribute to a negative outlook, including the risks associated with unexpected safety events, efficacy concerns, and the potential for regulatory hurdles impacting their drug development pipeline. The company reported substantial net losses of $235.5 million for 4Q24 and $913.8 million for FY24, which raises concerns about its financial stability and ability to fund ongoing research and operational expenses. Furthermore, the uncertain market dynamics, potential delays in product launches, and the looming threat of competition and generic entrants could severely hinder the company's revenue generation potential.
This aggregate rating is based on analysts' research of Insmed and is not a guaranteed prediction by Public.com or investment advice.
Insmed (INSM) Analyst Forecast & Price Prediction
Start investing in Insmed (INSM)
Order type
Buy in
Order amount
Est. shares
0 shares